Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
Harvard Business School
McKesson
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Teplizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Teplizumab: Patents, clinical trial progress, indications

Teplizumab is an investigational drug.

There have been 8 clinical trials for Teplizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2009.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and Glucose Intolerance. The leading clinical trial sponsors are MacroGenics, Eli Lilly and Company, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recent Clinical Trials for Teplizumab
TitleSponsorPhase
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)ActoBio TherapeuticsPhase 1/Phase 2
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)TFS Trial Form SupportPhase 1/Phase 2
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)Intrexon T1D Partners, LLCPhase 1/Phase 2

See all Teplizumab clinical trials

Clinical Trial Summary for Teplizumab

Top disease conditions for Teplizumab
Top clinical trial sponsors for Teplizumab

See all Teplizumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKesson
AstraZeneca
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.